Omalizumab is a monoclonal antibody used to treat allergic asthma. Omalizumab functions by binding to IgE, preventing it from reaching mast cells to induce degranulation. The net effect is a decreased release of histamine and other inflammatory mediators from mast cells, which can thereby relieve the symptoms of allergic asthma.

Key Points

  • Omalizumab
    • Mechanism
      • Antibody against IgE
        • Prevents IgE binding to and cross-linking the high-affinity IgE receptor (FcεRI) on mast cells and basophils
        • Inhibits degranulation and release of inflammatory mediators normally generated in response to allergens
    • Clinical Use
      • Severe allergic asthma 
        • Most effective in cases where patients have high serum IgE levels, with disease resistant to steroids and beta-2 agonists